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eBox. Eligibility and Exclusion Criteria
Eligibility Criteria 1. Clinical diagnosis of presumed autoimmune T1D as indicated by age of diagnosis <10 years or documented positive diabetes-related autoantibodies* 2. Age: 12 to <20 years 3. Duration of T1D: ≥1 years 4. Current insulin administration using either insulin pump or multiple daily injections of insulin (at least 3 shots per day) for the last three months, with no plans to switch the modality of insulin administration during the next 6 months (e.g., injection user switching to a pump, pump user switching to injections) 5. Hemoglobin A1c: 7.5% -<10.0% from point of care measurement or local lab on day of screening visit or within 1 month prior 6. BMI: ≥85th percentile adjusted for age and sex 7. Total daily dose of insulin: >0.8 units per kg per day 8. Average of ≥3 Self-Monitoring Blood Glucose (SMBG) tests per day prior to initiating study and from download of study-provided blood glucose meter following screening visit 9. Available for at least 6 months of follow-up, has home phone (or access to phone), and willing to be contacted by clinical site staff 10. Expected to comply with protocol in investigator's judgment Exclusion Criteria 11. Use of non-insulin medications for blood glucose control within prior 6 months or planning to use within next 6 months (other than study drug) 12. Use of medications for weight reduction (such as: Belviq (lorcaserin), Qsymia (Phentermine + topiramate), Orlistat (xenical)) within the prior 6 months or planning to use within next 6 months 13. Use of a medication such as stimulants, psychotropic agents and oral/inhaled glucocorticoids that could affect weight gain or glycemic control or planning to use within the next 6 months 14. Any condition that in the judgment of the investigator will adversely affect the completion of the protocol. 15. Females: pregnant, lactating, or intending to become pregnant within the next 34 weeks β 16. Clinical diagnosis of celiac disease that is in poor control as defined by most recent tissue transglutaminase (tTG) that is in the abnormal range 17. History of ≥1 DKA events in the past 3 months 18. History of ≥1 severe hypoglycemic events (cognitive impairment that required assistance to treat) in the past 3 months 19. History of anemia or vitamin B12 deficiency in the past 2 years 20. Participation in an intervention study in the past 3 months 21. Serum creatinine level greater than the upper limit of normal for an adult 22. Liver enzymes (ALT and AST) greater than 2.5 times upper limit of normal *For randomization, presence of at least one of the diabetes-related autoantibodies [Insulin autoantibodies (IAA) at diagnosis prior to initiation of insulin, Islet cell antibodies (ICA), Anti-GAD (GAD65), Anti-IA2 (IA2), Zinc Transporter 8 (ZnT8)] must have been documented either from medical records or new laboratory measurement (excluding IAA) sent to central lab for participants who were ≥10 years old at diagnosis. β Negative urine pregnancy test required for all females An effective contraceptive method or abstinence required for all females who have experienced menarche eFigure 1 (0, 1) 1 (1, 1) 1 (1, 1) 1 (0, 1) 1 (1, 1) 1 (1, 1)
Change in Area under the Curve 70 mg/dL c -mean (95% confidence interval)
0 (-0, 1) 0 (-0, 1) 0 (-0, 1) 0 (-0, 1) 0 (-0, 1) 0.32 0 (-0, 0) 0.78 0.10 a Linear mixed models were adjusted for random center effects and the baseline outcome measure. b Linear mixed models were adjusted for random center effects and the baseline outcome measure. A rank transformation of the change in the outcome measure was used to obtain test of significance c Participants with detectable non-fasting C-peptide at screening visit were given the option to have an MMTT performed at randomization and 26 week visit. 17 participants in the metformin group and 17 in the placebo group had detectable peak C-peptide from MMTT at randomization and 26-weeks. A rank transformation of the change in the peak C-peptide was used to obtain test of significance in a linear regression model adjusted for the rank transformation of the baseline peak C-peptide.
